6,256 reports of this reaction
4.4% of all BORTEZOMIB reports
#2 most reported adverse reaction
NEUROPATHY PERIPHERAL is the #2 most commonly reported adverse reaction for BORTEZOMIB, manufactured by Takeda Pharmaceuticals America, Inc.. There are 6,256 FDA adverse event reports linking BORTEZOMIB to NEUROPATHY PERIPHERAL. This represents approximately 4.4% of all 141,037 adverse event reports for this drug.
Patients taking BORTEZOMIB who experience neuropathy peripheral should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUROPATHY PERIPHERAL is moderately reported among BORTEZOMIB users, representing a notable but not dominant share of adverse events.
In addition to neuropathy peripheral, the following adverse reactions have been reported for BORTEZOMIB:
The following drugs have also been linked to neuropathy peripheral in FDA adverse event reports:
NEUROPATHY PERIPHERAL has been reported as an adverse event in 6,256 FDA reports for BORTEZOMIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUROPATHY PERIPHERAL accounts for approximately 4.4% of all adverse event reports for BORTEZOMIB, making it one of the most commonly reported side effect.
If you experience neuropathy peripheral while taking BORTEZOMIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.